New drug targets Hard-to-Treat cancers with missing gene
NCT ID NCT06810544
First seen Nov 06, 2025 · Last updated Jun 19, 2026 · Updated 37 times
Summary
This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, brain tumors, or other solid tumors that have progressed on standard treatments may join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Mayo Clinic Cancer Center
RECRUITINGRochester, Minnesota, 55905-0001, United States
Contact
-
Mayo Clinic Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic Scottsdale
RECRUITINGScottsdale, Arizona, 85259-5452, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 11065, United States
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611-2908, United States
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
-
Sibley Memorial Hospital
RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90995, United States
Contact
-
University of California at San Francisco
RECRUITINGSan Francisco, California, 94143-2202, United States
Contact
-
University of California, Irvine
RECRUITINGIrvine, California, 92686, United States
Contact
-
University of Utah, Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112-5500, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TNG456 (a PRMT5 inhibitor) and abemaciclib (Verzenio)
What this could lead to
If successful, this could lead to a new treatment option for certain hard-to-treat cancers that have an MTAP gene loss.
What could go wrong
This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may not work or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.